An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study (MILESTONE℠)

Trial Profile

An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study (MILESTONE℠)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Fampridine (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms MILESTONE
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 07 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top